APVO News and Press, Aptevo Therapeutics Inc. From 11/10/22

Aptevo Therapeutics press release ( NASDAQ: APVO ): Q3 GAAP EPS of -$1.50 beats by $0.14 . Aptevo had cash, cash equivalents and restricted cash of $22.6 million as of September 30, 2022. This includes $0.4 million of restricted cash that was released in October 2022. ...

Company to Present New APVO436 Expansion Phase Trial Data at Upcoming American Society of Hematology Annual Meeting and Exposition SEATTLE, WA / ACCESSWIRE / November 10, 2022 / Aptevo Therapeutics Inc. ("Aptevo" or the "Company") (NASDAQ:APVO), a clinical-stage biotechnology company fo...

ALG.APV-527 Demonstrates Favorable Preclinical Efficacy and Safety Compared to a First Generation 4-1BB Antibody ALG.APV-527 Rapidly Progressing to Clinical Development for Evaluation in the Treatment of Solid Tumors after Receipt of IND Clearance from the US Food and Drug Administratio...

Company to Present New Data from On-Going Phase 1b Trial Evaluating Lead Candidate APVO436 for the Treatment of Acute Myeloid Leukemia SEATTLE, WA / ACCESSWIRE / November 3, 2022 / Aptevo Therapeutics Inc. ("Aptevo" or the "Company") (NASDAQ:APVO), a clinical-stage biotechnology company...

Alligator Bioscience and Aptevo Therapeutics ( NASDAQ: APVO ) said the U.S. Food and Drug Administration had issued a "may proceed" notification to their investigational new drug application for ALG.APV-527 , to treat 5T4-expressing tumor antigens in multiple solid tumor t...

Drug Candidate progressing to the clinic for evaluation in the treatment of 5T4-expressing tumor antigens in multiple solid tumor types LUND, SWEDEN and SEATTLE WA / ACCESSWIRE / September 19, 2022 / Alligator Bioscience AB (" Alligator ") and Aptevo Therapeutics ("Aptevo") today anno...

Aptevo Therapeutics press release ( NASDAQ: APVO ): Q2 GAAP EPS of $5.58. Aptevo had cash, cash equivalents and restricted cash of $30 million as of June 30, 2022. For further details see: Aptevo Therapeutics GAAP EPS of $5.58

SEATTLE, WA / ACCESSWIRE / August 11, 2022 / Aptevo Therapeutics Inc. ("Aptevo" or the "Company") (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on its proprietary ADAPTIR™ and ADAPTIR-FLEX™ platform technolo...

DocuSign (DOCU) -25% on Q1 earnings release. RISE Education Cayman (REDU) -24%. Stitch Fix (SFIX) -15% on FQ3 earnings release. DBV Technologies (DBVT) -15%. Caribou Biosciences (CRBU) -13% amid new data for CAR-T therapy for non-Hodgkin lymphoma. Applied UV (AUV...

Aptevo Therapeutics (NASDAQ:APVO) traded higher in the morning hours Thursday after the clinical-stage biotech announced new remission data on four additional patients enrolled in its Phase 1b expansion trial for lead candidate APVO436 in acute myeloid leukemia (AML). According to early data ...